UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO
BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA
FROM THE PHASE 3 SELECT-PSA 2 STUDY

a 2021

UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI et. al.

Basic information

Original name

UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY

Authors

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN and W. TILLETT

Edition

2021

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1136/annrheumdis-2021-eular.1066

UT WoS

000692629300490

Keywords in English

upadacitinib, psoriatic arthritis, Janus kinase inhibitor

Abstract

V originále

Upadacitinib (UPA) is an oral Janus kinase inhibitor currently under evaluation for the treatment of psoriatic arthritis (PsA). Previous 24-week results from the SELECT-PsA 2 study in patients with PsA and prior inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) demonstrated UPA efficacy with a safety profile consistent with that observed in rheumatoid arthritis.

Citovat

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN and W. TILLETT. UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY. 2021. Available from: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.

@proceedings{1841042,
   author = {Mease, P.J. and Lertratanakul, A. and Papp, K. and Van den Bosch, F. and Tsuji, S. and Dokoupilová, Eva and Keiserman, M. and Bu, X. and Chen, L. and Mccaskill, R. and Zueger, P. and McdearmonandBlondell, E. and Pangan, A. and Tillett, W.},
   doi = {http://dx.doi.org/10.1136/annrheumdis-2021-eular.1066},
   keywords = {upadacitinib, psoriatic arthritis, Janus kinase inhibitor},
   language = {eng},
   title = {UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY},
   url = {https://ard.bmj.com/content/80/Suppl_1/312.1},
   year = {2021}
}

TY  - CONF
ID  - 1841042
AU  - Mease, P.J. - Lertratanakul, A. - Papp, K. - Van den Bosch, F. - Tsuji, S. - Dokoupilová, Eva - Keiserman, M. - Bu, X. - Chen, L. - Mccaskill, R. - Zueger, P. - Mcdearmon-Blondell, E. - Pangan, A. - Tillett, W.
PY  - 2021
TI  - UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY
KW  - upadacitinib, psoriatic arthritis, Janus kinase inhibitor
UR  - https://ard.bmj.com/content/80/Suppl_1/312.1
N2  - Upadacitinib (UPA) is an oral Janus kinase inhibitor currently under evaluation for the treatment of psoriatic arthritis (PsA). Previous 24-week results from the SELECT-PsA 2 study in patients with PsA and prior inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) demonstrated UPA efficacy with a safety profile consistent with that observed in rheumatoid arthritis.
ER  -

MEASE, P.J., A. LERTRATANAKUL, K. PAPP, F. VAN DEN BOSCH, S. TSUJI, Eva DOKOUPILOVÁ, M. KEISERMAN, X. BU, L. CHEN, R. MCCASKILL, P. ZUEGER, E. MCDEARMON-BLONDELL, A. PANGAN and W. TILLETT. \textit{UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY}. 2021. Available from: https://dx.doi.org/10.1136/annrheumdis-2021-eular.1066.

Detailed Information on Publication Record